|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
APROTININ IS INCOMPATIBLE WITH THE DRUG
|
CO-ADMINISTRATION WITH BUPROPION MAY ALTER THE SEIZURE THRESHOLD
|
CORTICOSTEROIDS CAN DECREASE SERUM CONCENTRATION OF ANTIMUSCARINIC AGENTS
|
CORTICOSTEROIDS CAN DECREASE SERUM CONCENTRATION OF ANTIMUSCARINIC AGENTS
|
CORTICOSTEROIDS CAN DECREASE SERUM CONCENTRATION OF ANTIMUSCARINIC AGENTS
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
MAY CAUSE HYPERGLYCEMIA LEADING TO LOSS OF DIABETIC CONTROL
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
CONCURRENT USE MAY REDUCE THE EFFICACY OF SERMORELIN
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS. STEROIDS DECREASE SERUM CONCENTRATION OF SALICYLATES
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|